Psychedelics: When is it a bad idea? - #PsychedeRx Bonus Episode No. 1

09/16/21 • 23 min

1 Listener

Over the ten episodes in this series, it’s clear that we are enthusiastic about the future of psychedelic medicines. There are so many potential applications for responsible, physician-assisted therapies that it almost seems as though psychedelics are a silver bullet, or a little black dress - perfect for any occasion and applicable to myriad diseases and conditions.

Not to contradict ourselves, but there are definitely situations in which psychedelic medicines are not only ineffective, but ill-advised or flat out a bad idea. We hope to provide responsible and balanced information to our listeners and believe that we have done so. The PTSD episode, you heard from the leaders of Heroic Hearts and Heroic Hearts UK about their non-negotiable exclusion criteria. But the same way you heard emotional personal stories about their success, we thought it imperative to share with you a story about why not everyone and not everything can be helped with psychedelic medicines and why responsible use is the only possible solution.

We give our special thanks to Dr. Erika Ross for sharing the story that changed her life. This one is for Kreg.

We give our special thanks to Dr. Erika Ross for sharing the story that changed her life. This one is for Kreg.

Previous Episode

#PsychedeRx Episode 10: Investing in New Frontiers of the Psychedelic Renaissance

New molecules, new IP, new opportunities. How can investors be induced to support the massive, but necessary funds required to support the important and carefully regulated research necessary to bring psychedelic therapies to market. Not to be crass, but if something isn’t going to bring a profit, it’s unlikely to receive much funding, regardless of how much good it might do, certainly not enough to cover the massive costs of bringing a disruptive therapy to market. Companies like Cybin and Bright Minds Bio are looking at modifications to create new IP, improved efficacy, and new delivery mechanisms.

With investment validations now taken care of, we need to address issues around delivery of care. Are we prepared to shift to a model of care that moves from weekly one-hour sessions to intensive, multi-hour sessions that require new paradigms that have never been tried? Before you answer, let us ask you another question: with between 11 and 20 out of every 100 US Veterans suffering from PTSD, how can we afford not to try?

Clara Burtenshaw, co-founder of Neo Kuma Ventures created the first European Fund dedicated to psychedelics shared with us her motivations, both professional and personal, for focusing on this space. We visited with Wavepaths CEO Mendel Kaelen about their founding principles and objectives; we explore Kernel’s entre into the psychedelic research space, and we revisit Doug Drysdale, CEO of Cybin. These are the folks to watch for the future of psychedelic medicines and the healthcare revolution that is coming your way.

It has been our pleasure to bring to you this series - this passion project to understand and share the opportunities, challenges, history, and future of psychedelic medicine.

Humbly,

Arun and JoJo

This series is only possible because of the generosity of spirit, time, resources, and dreams of our guests and contributors. A special thanks to Sharena Rice for her excellent research. Romeo Racz for technical support. Last but not the least, the unsung hero of our podcast series is our sound engineer, Mr. Swaminathan ThiruGnanaSambandam who did the mixing and mastering of audio.

Next Episode

SKRAPS NeuroTech NewsHour: Sep 21

Join us to listen to the bi-weekly news round up on all things #NeuroTech and #BioelectronicMedicine.
This week we talk about academic news with Cleveland NeuroTech Entrepreneurs workshop, UConn hiring spree in Engineering with focus on NeuroTech.
On industry side, we cover Rune Labs, Tivic Health, Opinions on Nyxoah and their FDA breakthrough designation, Axonics/ Medtronic Patent Rulings.
Plus we are joined by Victor Pikov of Medipace & TRI, Khalid Ishaque of Bioinduction for the new around.
Join us for our biweekly Newshour on Clubhouse. We post details on LinkedIn and Twitter.